All In Biotech

Drug Trial Radar · NCT06893250

Orthobiologic Treatment for Knee Osteoarthritis

Orthobiologic Treatment for Knee Osteoarthritis (Ortobiologisk Behandling av Kneleddsartrose)

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 23, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
University Hospital of North NorwayAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized clinical trial is to compare treatment for osteoarthritis in the knee using platelet rich plasma (PRP) or adipose stem cells (ADS). The main questions it aims to answer are: * Will the patients clinically benefit from the treatment, and if so, which treatment is better? * Will there be radiological findings to support this? Participants will be randomized into one of four groups: PRP, ADS, PRP + ADS or placebo treatment (saline) and will be examined and get an X-ray and MRI of the knee taken at inclusion and after 1 and 2 years.

Conditions

  • Osteoarthritis Knee

Interventions

  • PRP injectionBiological

    Platelet rich plasma, blood from the patient that is centrifuged.

  • ADSTEM Inj. (Adult human mesenchymal stem cells)Biological

    Adipose tissue stem cells, from abdominal fat.

  • InjectionBiological

    PRP + adipose tissue stem cells

  • Saline (NaCl 0,9 %) (placebo)Biological

    Sterile saline injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. KOOS (The Knee injury and Osteoarthritis Outcome Score)Time frame: Evaluated during 2 years of follow up (6 weeks, 12 weeks, 6 months, 1 year, 2 years)
  2. WOMAC score (Western Ontario og McMaster Universities Osteoarthritis Index)Time frame: Evaluated during 2 years of follow up (6 weeks, 12 weeks, 6 months, 1 year, 2 years)
  3. VAS (Visual analogue scale)Time frame: Evaluated during 2 years of follow up (6 weeks, 12 weeks, 6 months, 1 year, 2 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital in Northern Norway

    Tromsø, Tromsø, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.